| 영문 | carcinoma in situ | 한글 | 상피내암종 |
|---|---|---|---|
| 설명 | 신체의 내부나 외부를 쌓고 있는 조직을 상피라고 한다. 이 상피의 아래에는 대개 상피를 지지하고 있는 조직의 위에 존재한다. 그리고 이 지지조직과 상피 사이에는 기저막이라는 막이 있어서 상피와 지지조직을 구분해 준다. 암종(carcinoma)란 상피의 세포가 악성 변화를 하여 생기는 암을 말한다. 제자리암종이란 암종의 한 종류로 암종이 기저막을 벗어나지 못하고 상피내 즉, 제자리에 머물러 있는 경우를 말한다. |
||
| 영문 | thyroid carcinoma | 한글 | 갑상샘암종 |
|---|---|---|---|
| 설명 | 갑상샘에 생긴 상피세포로 이루어진 악성종양물. 병리조직학적인 형태에 따라 유두상, 소포상, 역형암종 및 수질암종, 림프종 등으로 나눌 수 있다. 다양한 원인이 있으나, 일부에서는 방사선폭로에 의해 발생한다. 치료는 수술, 방사성 옥소, T4 억제요법 등이 사용된다. |
||
| 영문 | bronchogenic carcinoma | 한글 | 기관지원성 암종 |
|---|---|---|---|
| 설명 | 폐의 기관지 세포에서 기원하는 종양. 폐암의 종류에서 가장 흔한 형태(90%이상)이다. 현미경적 소견에 따라 샘암종, 큰세포암종, 소세포(작은세포) 암종의 4가지로 나눈다. 이중에서 편평세포암종이 가장 흔한 형태이다. 임상적으로는 비소세포폐암(non-small cell lung cancer)와 소세포폐암(small cell lung cancer)로 구분을 하는데, 비소세포폐암의 경우 종양세포의 성장이 느리고 수술적 제거가 치료의 기본이 되고 예후도 좋은 반면, 소세포폐암의 경우에는 암세포의 성장이 매우 빠르고 치료도 방사선치료를 기본으로 하며 예후도 비소세포폐암에 비해서 좋지가 못하다. |
||
| 영문 | embryonal carcinoma | 한글 | 배아암종 |
|---|---|---|---|
| 설명 | 생식세포에서 생기는 암종의 하나로 대부분 고환에서 발생한다. 드물게는 종격동에서도 발생한다. 40~50대의 남성에게 많으나, 이보다 낮은 연령층에서도 나타난다. 육안적으로는 회백색의 분엽을 보이는 덩어리를 형성하며, 고환 악성 종양 중 예후가 좋은 편이다. 치료의 원칙은 가급적 신속하게 원발소를 절제하고 예상되는 전이병터에 대하여 방사선 조사요법을 행해야 한다. 태생암종 방사선요법에 대하여 매우 감수성이 높기 때문에 병기가 초기이면 90% 이상의 치료가 기대된다. 그리고 화학요법제에 의해 그 치료성과가 상승하고 있다. |
||
| 영문 | carcinoma | 한글 | 암종 |
|---|---|---|---|
| 설명 | 암종이란 상피세포(-신체의 내부나 외부를 쌓고 있는 조직을 상피라고 하고, 상피를 이루고 있는 세포를 상피세포라고 한다)의 과도한 증식에의한 악성종양을 이르는 말이다. |
||
| ACC | accommodation; acetyl coenzyme A carboxylase; acinic cell carcinoma; acute care center; adenoid cyst... |
|---|---|
| CIS | Carcinoma In Situ |
| CIN | 3, CIN III cervical intraepithelial neoplasia, grade 3 (severe dysplasia and carcinoma in situ) |
| CIS | carcinoma in situ; catheter-induced spasm; central inhibitory state; Chemical Information Service; c... |
| DCIS | ductal carcinoma in situ |
| AIS | Adeno-carcinoma in situ |
|---|---|
| CIS | Carcinoma in Situ |
| DCIS | Duct carcinoma in situ |
| DCIS | Ductal Carcinoma In Situ |
| LCIS | Lobular carcinoma in situ |
| carcinoma in situ | Cancer that involves only the cells in which it began and has not spread to other tissues. Lobular carcinoma in situ is found in the lobules of the breast. Ductal carcinoma in situ (also called intraductal carcinoma) arises in the ducts. (16 Dec 1997) |
|---|---|
| ductal carcinoma in situ | <oncology, tumour> A cancer inside the ducts of breast that has not grown through the wall of the duct into the surrounding tissues. Sometimes referred to as a precancer. Good prognosis is involved with in situ cancers. (09 Oct 1997) |
| lobular carcinoma in situ | <tumour> Carcinoma of the breast in which small tumour cells fill preexisting acini within lobules, without invading the surrounding stroma. Synonym: lobular carcinoma in situ, lobular neoplasia. (05 Mar 2000) |
| other-directed | Pertaining to a person readily influenced by the attitudes of others. (05 Mar 2000) |
| transferases (other substituted phosphate groups) | <enzyme> A class of enzymes that transfers substituted phosphate groups. Registry number: EC 2.7.8 (12 Dec 1998) |
| attachment sites | <microbiology, molecular biology> Particular loci in both bacterial and phage DNA molecules at which phage DNA is integrated into the bacterial DNA by recombination between these sites. (12 Dec 1998) |
| binding sites | The reactive parts of a macromolecule that directly participate in its specific combination with another molecule. (12 Dec 1998) |
| binding sites, antibody | Local surface sites on antibodies which react with antigen determinant sites on antigens. They are formed from parts of the variable regions of the fab fragment of the immunoglobulin. (12 Dec 1998) |
| chromosome fragile sites | Heritable sensitive regions of chromosomes which show up in vitro as non-staining bands. They are associated with chromosome breakage and other aberrations, and, when located on sex chromosomes, they produce phenotypic abnormalities. No abnormal phenotype has been definitely identified with autosomal fragile sites, but some rare autosomal recessive disorders may be due to homozygosity for fragile sites. Fragile sites are designated by the letters "fra" followed by the designation for the specific chromosome and locus. (12 Dec 1998) |
| contact sites A | Developmentally regulated adhesion sites that appear on the ends of aggregation competent Dictyostelium discoideum at the stage when the starved cells begin to come together to form the grex. Originally detected by the use of Fab fragments of polyclonal antibodies, raised against aggregation competent cells and adsorbed against vegetative cells, to block adhesion in EDTA containing medium. (Cell cell adhesion mediated by contact sites A, unlike that mediated by contact sites B, is not divalent cation sensitive). The fact that a mutant deficient in csA behaves perfectly normally in culture is puzzling. (18 Nov 1997) |
| contact sites B | Developmentally regulated adhesion sites that appear on the ends of aggregation competent Dictyostelium discoideum at the stage when the starved cells begin to come together to form the grex. Originally detected by the use of Fab fragments of polyclonal antibodies, raised against aggregation competent cells and adsorbed against vegetative cells, to block adhesion in EDTA containing medium. (Cell cell adhesion mediated by contact sites A, unlike that mediated by contact sites B, is not divalent cation sensitive). The fact that a mutant deficient in csA behaves perfectly normally in culture is puzzling. (18 Nov 1997) |
| crohn disease: sites | <radiology> Oesophagus: rare, stomach (2-20%): granulomatous gastritis, pseudo-post Bilroth-I appearance, ramshorn sign, antral-duodenal fistula, duodenum (4-10%): almost always associated with gastric involvement, bulb and proximal half of duodenum, small bowel (80%): regional enteritis, terminal ileum (alone/in combination): 95%, jejunum/ileum: 15%, commonly associated with medial caecal defect, colon (22-55%): granulomatous colitis, particularly on the right side, transverse stripe sign: contrast within coarse mucosal folds, rectum (35-50%) see: Crohn disease (12 Dec 1998) |
| sequence tagged sites | Short, tagged tracts of DNA sequence that are used as landmarks in genome mapping. In most instances, 200 to 500 base pairs of sequence define a sequence tagged site (sts) that is operationally unique in the human genome (i.e., can be specifically detected by the polymerase chain reaction in the presence of all other genomic sequences). The overwhelming advantage of stss over mapping landmarks defined in other ways is that the means of testing for the presence of a particular sts can be completely described as information in a database. (12 Dec 1998) |
| sequence-tagged sites | Short stretches of DNA sequences that can be detected by use of the polymerase chain reaction. (05 Mar 2000) |
| immunologically privileged sites | Sites where allografts are not readily rejected, probably because these particular areas have poor lymphatic drainage. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|